ofloxacin has been researched along with Keratitis in 56 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Keratitis: Inflammation of the cornea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% levofloxacin eyedrops on the treatment of acute bacterial conjunctivitis and bacterial keratitis." | 9.09 | [Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis]. ( Chen, F; Hu, Y; Zhang, M, 2000) |
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 7.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "5% levofloxacin in rabbits, and to determine its improved efficacy against experimental keratitis." | 7.76 | Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. ( Chen, H; Jiang, HR; Wu, XG; Xin, M; Yang, LN, 2010) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 7.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| "Six cases of microbial keratitis treated with multiple topical medications, including topical ofloxacin, resulted in corneal precipitates and poor wound healing." | 7.74 | Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. ( McElvanney, A; Mitra, A; Tsesmetzoglou, E, 2007) |
| "3% ofloxacin solution) on methicillin-resistant Staphylococcus aureus (MRSA) keratitis were compared in a rabbit model." | 7.73 | Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits. ( Fukaya, Y; Hirata, H; Kamata, Y; Kambara, Y; Kurasawa, N; Kurita, A; Naito, A; Nakaya, S; Ohashi, Y; Sato, M; Shirasawa, E; Toyoda, Y; Tsuruga, H; Wada, T, 2006) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 7.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities." | 7.72 | Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. ( Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M, 2004) |
| " In this study we investigate the emergence of fluoroquinolone (ciprofloxacin, levofloxacin) resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis." | 7.72 | Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. ( Alfonso, EC; Marangon, FB; Miller, D; Muallem, MS; Romano, AC, 2004) |
| "Taken together, our susceptibility and time kill data failed to demonstrate convincing differences in the susceptibility of SA and PA keratitis isolates to levofloxacin, ciprofloxacin, and ofloxacin." | 7.71 | An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001) |
| "Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective." | 7.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| "To compare the antibacterial effect of povidone-iodine (PI) with that of ofloxacin in an experimental model of bacterial keratitis." | 7.70 | Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. ( Goldberg, MA; Lustbader, J; MacDowell, AL; Melki, SA; Safar, A; Scharper, M; Scharper, P; Yaghouti, F; Zeligs, B, 2000) |
| "Bacterial keratitis is a serious infectious ocular disease requiring prompt treatment to prevent frequent and severe visual disabilities." | 5.32 | A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. ( Boldrini, E; Campa, M; Celandroni, F; Davini, P; Ghelardi, E; Parisio, E; Salvetti, S; Senesi, S; Tavanti, A, 2004) |
| "Bacterial keratitis (BK) presentations are often treated using the commercially available second-generation fluoroquinolones ciprofloxacin 0." | 5.22 | The clinical treatment of bacterial keratitis: A review of drop instillation regimes. ( Essex, RW; Maddess, T; Pearce, JG, 2022) |
| "3% levofloxacin eyedrops on the treatment of acute bacterial conjunctivitis and bacterial keratitis." | 5.09 | [Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis]. ( Chen, F; Hu, Y; Zhang, M, 2000) |
| " A MEDLINE search was conducted using the following search terms: moxifloxacin or gatifloxacin; levofloxacin; minimum inhibitory concentration or prevention or prophylaxis; keratitis or endophthalmitis." | 4.84 | Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. ( Scoper, SV, 2008) |
| " This study aims to investigate the effectiveness of ofloxacin-loaded contact lenses as prolonged release devices for the treatment of bacterial keratitis." | 3.91 | Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model. ( Chauhan, A; Gibson, D; Schultz, G; Silva, BO; Ubani-Ukoma, U, 2019) |
| "The aim of the present study was to develop novel ofloxacin (OFX)-loaded nanostructured lipid carrier (NLC)-based inserts for ocular application for treatment of bacterial keratitis." | 3.81 | Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. ( Bozbıyık, Dİ; Eğrilmez, S; Ertan, G; Gökçe, EH; Özer, Ö; Üstündağ-Okur, N, 2015) |
| "Corneal cross-linking (CXL) with riboflavin is being used more frequently for the treatment of therapy-resistant microbial keratitis, since increasing drug resistance and specific pathogens, e." | 3.80 | [Corneal cross-linking in microbial keratitis to prevent à chaud keratoplasty: a retrospective case series]. ( Ammermann, C; Cursiefen, C; Hermann, M, 2014) |
| "The objective of the present study was to evaluate the effectiveness of topically applied gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis in a rabbit model." | 3.78 | Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. ( Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W, 2012) |
| "5% levofloxacin in rabbits, and to determine its improved efficacy against experimental keratitis." | 3.76 | Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis. ( Chen, H; Jiang, HR; Wu, XG; Xin, M; Yang, LN, 2010) |
| "Six cases of microbial keratitis treated with multiple topical medications, including topical ofloxacin, resulted in corneal precipitates and poor wound healing." | 3.74 | Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis. ( McElvanney, A; Mitra, A; Tsesmetzoglou, E, 2007) |
| "In the rabbit keratitis model, the ocular inflammation was significantly reduced by gatifloxacin as compared to levofloxacin but there was no significant difference between the groups in the number of viable bacteria." | 3.74 | Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis. ( Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T, 2008) |
| "Taurolidine is a broad-spectrum, non antibiotic antimicrobial agent, not previously tested against the common causes of bacterial keratitis." | 3.73 | Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. ( Gurkan, T; Oguz, E; Oguz, H; Ozbilge, H, 2005) |
| "3% ofloxacin solution) on methicillin-resistant Staphylococcus aureus (MRSA) keratitis were compared in a rabbit model." | 3.73 | Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits. ( Fukaya, Y; Hirata, H; Kamata, Y; Kambara, Y; Kurasawa, N; Kurita, A; Naito, A; Nakaya, S; Ohashi, Y; Sato, M; Shirasawa, E; Toyoda, Y; Tsuruga, H; Wada, T, 2006) |
| "The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities." | 3.72 | Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. ( Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M, 2004) |
| " In this study we investigate the emergence of fluoroquinolone (ciprofloxacin, levofloxacin) resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis." | 3.72 | Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. ( Alfonso, EC; Marangon, FB; Miller, D; Muallem, MS; Romano, AC, 2004) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "Overall, moxifloxacin was the most effective of the four fluoroquinolones in reducing CFU/cornea in the rabbit model of gram-negative keratitis." | 3.72 | Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. ( Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA, 2004) |
| "To determine the in vitro efficacy of levofloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae and Streptococcus viridans isolates recovered from clinical cases of keratitis and endophthalmitis." | 3.72 | Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. ( Alfonso, EC; Miller, D, 2004) |
| "Taken together, our susceptibility and time kill data failed to demonstrate convincing differences in the susceptibility of SA and PA keratitis isolates to levofloxacin, ciprofloxacin, and ofloxacin." | 3.71 | An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. ( Gordon, YJ; Husted, RC; Karenchak, LM; Kowalski, RP; Pandya, AN; Ritterband, DC; Romanowski, EG; Shah, MK, 2001) |
| "Topical treatment of experimental Staphylococcus keratitis with ciprofloxacin-PSS, ciprofloxacin, or ofloxacin was effective." | 3.70 | Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. ( Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) |
| "To compare the antibacterial effect of povidone-iodine (PI) with that of ofloxacin in an experimental model of bacterial keratitis." | 3.70 | Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. ( Goldberg, MA; Lustbader, J; MacDowell, AL; Melki, SA; Safar, A; Scharper, M; Scharper, P; Yaghouti, F; Zeligs, B, 2000) |
| " The combined effects of ovoM and the new quinolone, ofloxacin (OFLX) on experimental Pseudomonas aeruginosa keratitis were investigated." | 3.69 | Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis. ( Kamata, R; Maeda, H; Matsumoto, K; Miyagawa, S; Okamura, R, 1994) |
| "Cefazolin resistance was seen in 13." | 1.72 | Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers. ( Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T, 2022) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Bacterial keratitis is a serious infectious ocular disease requiring prompt treatment to prevent frequent and severe visual disabilities." | 1.32 | A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis. ( Boldrini, E; Campa, M; Celandroni, F; Davini, P; Ghelardi, E; Parisio, E; Salvetti, S; Senesi, S; Tavanti, A, 2004) |
| "Marginal keratitis is postulated, but not proven, to be caused by an enhanced immune response to Staphylococcus aureus antigens." | 1.31 | Dissecting folliculitis of the scalp with marginal keratitis. ( Burrows, NP; Meyer, P; Sivakumaran, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (14.29) | 18.2507 |
| 2000's | 29 (51.79) | 29.6817 |
| 2010's | 15 (26.79) | 24.3611 |
| 2020's | 4 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, F | 1 |
| Li, X | 1 |
| Cai, S | 1 |
| Xin, G | 1 |
| Wang, Y | 1 |
| Du, D | 1 |
| He, S | 1 |
| Huang, B | 1 |
| Guo, X | 1 |
| Zhao, H | 1 |
| Zhang, R | 1 |
| Ma, L | 1 |
| Liu, Y | 1 |
| Du, Q | 1 |
| Wei, Z | 1 |
| Xing, Z | 1 |
| Liang, Y | 1 |
| Wu, X | 2 |
| Fan, C | 1 |
| Ji, C | 1 |
| Zeng, D | 1 |
| Chen, Q | 1 |
| He, Y | 1 |
| Liu, X | 1 |
| Huang, W | 1 |
| Soni, T | 1 |
| Gunasekaran, R | 1 |
| Das, S | 1 |
| Mitra, S | 1 |
| Prajna, NV | 1 |
| Prajna, L | 1 |
| Sharma, S | 1 |
| Mohamed, A | 1 |
| Pearce, JG | 1 |
| Essex, RW | 1 |
| Maddess, T | 1 |
| Sanap, SN | 1 |
| Bisen, AC | 1 |
| Kedar, A | 1 |
| Yadav, KS | 1 |
| Krishna, A | 1 |
| Akhir, A | 1 |
| Chopra, S | 1 |
| Mugale, MN | 1 |
| Bhatta, RS | 1 |
| Priyadarshini, SR | 1 |
| Behera, HS | 1 |
| Sahu, S | 1 |
| Dutta, A | 1 |
| Gandhi, P | 1 |
| Radhakrishnan, N | 1 |
| Khaitan, I | 1 |
| Srinivasan, M | 1 |
| Prajna, VN | 1 |
| Ubani-Ukoma, U | 1 |
| Gibson, D | 1 |
| Schultz, G | 1 |
| Silva, BO | 1 |
| Chauhan, A | 1 |
| Ammermann, C | 1 |
| Cursiefen, C | 1 |
| Hermann, M | 1 |
| Ustündağ-Okur, N | 2 |
| Gökçe, EH | 2 |
| Bozbıyık, Dİ | 2 |
| Eğrilmez, S | 2 |
| Ozer, O | 2 |
| Ertan, G | 2 |
| Chaudhry, NL | 1 |
| Przybek, J | 1 |
| Hamilton, A | 1 |
| Carley, F | 1 |
| Ranjan, A | 1 |
| Murthy, SI | 1 |
| Rathi, VM | 1 |
| Sangwan, VS | 1 |
| Scoper, SV | 1 |
| Elias, JA | 1 |
| Pandit, RT | 1 |
| Jhanji, V | 1 |
| Sharma, N | 1 |
| Vajpayee, RB | 1 |
| Jun, EJ | 1 |
| Chung, SK | 1 |
| Panagiotopoulos, M | 1 |
| Sönne, H | 1 |
| Kamiya, K | 1 |
| Ikeda, T | 1 |
| Aizawa, D | 1 |
| Shimizu, K | 1 |
| Wu, XG | 1 |
| Xin, M | 1 |
| Chen, H | 2 |
| Yang, LN | 1 |
| Jiang, HR | 1 |
| Jiang, H | 1 |
| Xu, Y | 1 |
| Yue, W | 1 |
| Yang, L | 1 |
| Song, Z | 1 |
| Liu, T | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Sotozono, C | 1 |
| Inagaki, K | 1 |
| Fujita, A | 1 |
| Koizumi, N | 1 |
| Sano, Y | 1 |
| Inatomi, T | 1 |
| Kinoshita, S | 1 |
| Zhang, M | 1 |
| Hu, Y | 1 |
| Chen, F | 1 |
| Holzer, MP | 1 |
| Sandoval, HP | 1 |
| Vargas, LG | 1 |
| Kasper, TJ | 1 |
| Vroman, DT | 1 |
| Apple, DJ | 1 |
| Solomon, KD | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 4 |
| Wallin, TR | 1 |
| Weikert, MP | 1 |
| Moshirfar, M | 1 |
| Marangon, FB | 1 |
| Miller, D | 2 |
| Muallem, MS | 1 |
| Romano, AC | 1 |
| Alfonso, EC | 2 |
| Dajcs, JJ | 4 |
| Thibodeaux, BA | 4 |
| Marquart, ME | 3 |
| Girgis, DO | 3 |
| Traidej, M | 2 |
| O'Callaghan, RJ | 5 |
| Gris, O | 1 |
| Güell, JL | 1 |
| Wolley-Dod, C | 1 |
| Adán, A | 1 |
| Solomon, R | 1 |
| Biser, SA | 1 |
| Donnenfeld, ED | 1 |
| Perry, HD | 1 |
| Doshi, SJ | 1 |
| Lee, CC | 1 |
| Caballero, AR | 2 |
| Ghelardi, E | 1 |
| Tavanti, A | 1 |
| Davini, P | 1 |
| Celandroni, F | 1 |
| Salvetti, S | 1 |
| Parisio, E | 1 |
| Boldrini, E | 1 |
| Senesi, S | 1 |
| Campa, M | 1 |
| Oguz, H | 2 |
| Ozbilge, H | 1 |
| Oguz, E | 1 |
| Gurkan, T | 1 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Mitra, A | 1 |
| Tsesmetzoglou, E | 1 |
| McElvanney, A | 1 |
| Mah, FS | 1 |
| Romanowski, EG | 2 |
| Dhaliwal, DK | 1 |
| Yates, KA | 1 |
| Gordon, YJ | 3 |
| Fukaya, Y | 1 |
| Kurita, A | 1 |
| Tsuruga, H | 1 |
| Naito, A | 1 |
| Nakaya, S | 1 |
| Sato, M | 1 |
| Kamata, Y | 1 |
| Hirata, H | 1 |
| Kambara, Y | 1 |
| Kurasawa, N | 1 |
| Wada, T | 2 |
| Toyoda, Y | 1 |
| Shirasawa, E | 1 |
| Ohashi, Y | 1 |
| Altaie, R | 1 |
| Fahy, GT | 1 |
| Cormican, M | 1 |
| Kida, T | 1 |
| Inoue, T | 2 |
| Tokushige, H | 1 |
| Naka, H | 1 |
| Sakaki, H | 1 |
| Hori, Y | 1 |
| Maeda, N | 1 |
| Kosaki, R | 1 |
| Tano, Y | 1 |
| Diamond, JP | 1 |
| White, L | 1 |
| Leeming, JP | 1 |
| Bing Hoh, H | 1 |
| Easty, DL | 1 |
| Miyagawa, S | 1 |
| Kamata, R | 1 |
| Matsumoto, K | 1 |
| Okamura, R | 1 |
| Maeda, H | 1 |
| Behrens-Baumann, W | 1 |
| Kowalski, RP | 2 |
| Karenchak, LM | 2 |
| Moreau, JM | 3 |
| Green, LC | 1 |
| Engel, LS | 1 |
| Hill, JM | 1 |
| Morlet, N | 1 |
| Minassian, D | 1 |
| Butcher, J | 1 |
| Melki, SA | 1 |
| Safar, A | 1 |
| Yaghouti, F | 1 |
| Scharper, P | 1 |
| Scharper, M | 1 |
| Zeligs, B | 1 |
| MacDowell, AL | 1 |
| Goldberg, MA | 1 |
| Lustbader, J | 1 |
| Chang-Godinich, A | 1 |
| Steinert, RF | 1 |
| Wu, HK | 1 |
| Pandya, AN | 1 |
| Husted, RC | 1 |
| Ritterband, DC | 1 |
| Shah, MK | 1 |
| Sivakumaran, S | 1 |
| Meyer, P | 1 |
| Burrows, NP | 1 |
| Austin, MS | 1 |
| Stroman, DW | 2 |
| Schlech, BA | 1 |
| Ke, TL | 1 |
| Ohadi, C | 1 |
| Litwin, KL | 1 |
| Moreira, H | 1 |
| Kwitko, S | 1 |
| Gauderman, WJ | 1 |
| Gritz, DC | 2 |
| Gwon, A | 2 |
| Jones, R | 1 |
| Lee, TY | 1 |
| Tang-Liu, D | 1 |
| Hubbard, BB | 1 |
2 reviews available for ofloxacin and Keratitis
| Article | Year |
|---|---|
The clinical treatment of bacterial keratitis: A review of drop instillation regimes.
Topics: Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratitis; Ofloxacin | 2022 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Ga | 2008 |
2 trials available for ofloxacin and Keratitis
| Article | Year |
|---|---|
[Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Conjunctivitis, Bacterial; Eye Infections, Bacterial | 2000 |
Risk factors for treatment outcome of suspected microbial keratitis. Ofloxacin Study Group.
Topics: Adolescent; Aged; Aged, 80 and over; Anti-Infective Agents; Cefuroxime; Cephalosporins; Eye Infectio | 1999 |
52 other studies available for ofloxacin and Keratitis
| Article | Year |
|---|---|
Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I.
Topics: Animals; Anti-Bacterial Agents; Emodin; Enterococcus faecium; Keratitis; Methicillin-Resistant Staph | 2014 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacte | 2022 |
Chitosan/HPMC-based mucoadhesive film co-loaded with fluconazole and ofloxacin for management of polymicrobial keratitis.
Topics: Chitosan; Drug Compounding; Drug Delivery Systems; Fluconazole; Humans; Keratitis; Ofloxacin | 2022 |
Topics: Anti-Bacterial Agents; Child; Corynebacterium; Eye Infections, Bacterial; Humans; Keratitis; Male; M | 2021 |
Toxic Keratitis After Application of Custard Apple Seed for Head Lice Infestation.
Topics: Administration, Ophthalmic; Adolescent; Adult; Animals; Annona; Anti-Bacterial Agents; Child; Eye Pa | 2019 |
Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Contact Lenses, Hydrophilic; Cornea; Drug Delivery S | 2019 |
[Corneal cross-linking in microbial keratitis to prevent à chaud keratoplasty: a retrospective case series].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Biological Dressings; C | 2014 |
Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis.
Topics: Animals; Anti-Bacterial Agents; Chitosan; Drug Carriers; Escherichia coli; Hydrogen-Ion Concentratio | 2014 |
Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis.
Topics: Animals; Biological Availability; Cornea; Drug Delivery Systems; Excipients; Eye Infections, Bacteri | 2015 |
Unique case of palytoxin-related keratitis.
Topics: Acrylamides; Animals; Anthozoa; Anti-Bacterial Agents; Aquaculture; Cnidarian Venoms; Drug Therapy, | 2016 |
Acute Bilateral Toxic Endotheliitis Following Alcohol Consumption.
Topics: Acute Disease; Adult; Alcohol Drinking; Anti-Bacterial Agents; Cataract; Cataract Extraction; Cornea | 2018 |
Primary Neisseria meningitidis Keratitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Drug Administration Schedule; Drug Therapy, | 2009 |
Intraoperative perforation of Descemet's membrane during "big bubble" deep anterior lamellar keratoplasty.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Child; Corneal Diseases; Corneal Transplanta | 2010 |
Toxic anterior segment syndrome after cataract surgery.
Topics: Aged; Anterior Eye Segment; Corneal Edema; Drug Therapy, Combination; Endotoxins; Female; Humans; Ke | 2010 |
Chronic granulomatous disease and serious unilateral keratitis with bilateral conjunctivitis: a rare case of external ocular disease.
Topics: Adult; Colitis, Ulcerative; Conjunctivitis; Dexamethasone; Drug Therapy, Combination; Functional Lat | 2011 |
A case of late-onset diffuse lamellar keratitis 12 years after laser in situ keratomileusis.
Topics: Betamethasone; Cornea; Drug Therapy, Combination; Humans; Keratitis; Keratomileusis, Laser In Situ; | 2010 |
Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis.
Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Bacterial Load; | 2010 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Child; Dibekacin; Eye Infections, Bacterial; Fe | 2002 |
Corneal flap complications in refractive surgery: Part 2: postoperative treatments of diffuse lamellar keratitis in an experimental animal model.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Corneal Stroma; Disease Mod | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
Effect of flap hinge placement on post-laser in situ keratomileusis wound healing in the presence of superior corneal vascularization.
Topics: Adult; Anti-Infective Agents; Corneal Edema; Corneal Neovascularization; Corneal Stroma; Corneal Top | 2003 |
Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Conjunctivitis, Bacterial; Cross-Sectional Studies; Drug Resis | 2004 |
Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; Endophthalmitis; Humans; Keratitis; Levofloxacin; Microbial Se | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fl | 2004 |
Diffuse lamellar keratitis and corneal edema associated with viral keratoconjunctivitis 2 years after laser in situ keratomileusis.
Topics: Adenovirus Infections, Human; Anti-Infective Agents; Astigmatism; Conjunctivitis, Viral; Corneal Ede | 2004 |
Candida parapsilosis keratitis following treatment of epithelial ingrowth after laser in situ keratomileusis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Debridement; Drug Therapy, Combination; Epithelium, | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye I | 2004 |
A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.
Topics: Adhesives; Administration, Topical; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Colon | 2004 |
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Ciprofloxacin; Colony Cou | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
Corneal deposits and topical ofloxacin--the effect of polypharmacy in the management of microbial keratitis.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Corne | 2007 |
Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corneal Stroma; Disease Models, Animal; Endotoxins; F | 2006 |
Antibiotic effects of WP-0405, a thermo-setting ofloxacin gel, on methicillin-resistant Staphylococcus aureus keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cil | 2006 |
Failure of Listeria monocytogenes keratitis to respond to topical ofloxacin.
Topics: Adolescent; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Eye Infections, Bacterial; Hu | 2006 |
Cytotoxic effects of the fluoroquinolone ofloxacin on stromal keratocytes.
Topics: Animals; Anti-Infective Agents; Corneal Stroma; Disease Models, Animal; Eye Infections, Bacterial; H | 2007 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluor | 2008 |
Three cases of idiopathic "multiple-parallel-line" endotheliitis.
Topics: Aged; Anti-Bacterial Agents; Betamethasone; Drug Therapy, Combination; Endothelium, Corneal; Glucoco | 2008 |
Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromatography, High Pressure Liquid; Ciprofloxac | 1995 |
Therapeutic intervention with chicken egg white ovomacroglobulin and a new quinolone on experimental Pseudomonas keratitis.
Topics: alpha-Macroglobulins; Animals; Cathepsin G; Cathepsins; Egg Proteins, Dietary; Eye Infections, Bacte | 1994 |
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye.
Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aqueous | 1996 |
Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.
Topics: Anti-Infective Agents; Biological Availability; Ciprofloxacin; Colony Count, Microbial; Cornea; Gram | 1998 |
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 1998 |
Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Colony Count, Microbial; Cornea; Disease Models, Animal; Eye Infecti | 2000 |
Late occurrence of diffuse lamellar keratitis after laser in situ keratomileusis.
Topics: Anti-Infective Agents; Cornea; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Keratitis | 2001 |
An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Eye Infec | 2001 |
Dissecting folliculitis of the scalp with marginal keratitis.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agen | 2001 |
Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Colony Count, Microbial; Corn | 2001 |
The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Colony Count, Microbi | 2001 |
Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dicarboxylic Acids; Disease | 1992 |
Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model.
Topics: Administration, Topical; Animals; Aqueous Humor; Chromatography, High Pressure Liquid; Disease Model | 1992 |